KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.

Nikolaus Marx, John E Deanfield, Johannes F E Mann, Rosario Arechavaleta, Stephen C Bain, Harpreet S Bajaj, Katrine Bayer Tanggaard, Andreas L Birkenfeld, John B Buse, Zaklina Davicevic-Elez, Cyrus Desouza, Scott S Emerson, Mads D M Engelmann, G Kees Hovingh, Silvio E Inzucchi, Pardeep S Jhund, Sharon L Mulvagh, Rodica Pop-Busui, Neil R Poulter, Søren Rasmussen, Shih-Te Tu, Darren K McGuire, SOUL Study Group

Circulation 151(23) 1639-1650

PMID40156843
PMCIDPMC12144549
DOI10.1161/CIRCULATIONAHA.125.074545
发表日期2025-03-29
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Both GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 (sodium-glucose cotransporter-2) inhibitors (SGLT2i) improve cardiovascular outcomes in people with type 2 diabetes and cardiovascular or chronic kidney disease. However, there are limited data about the effect of combining these agents on cardiovascular and safety outcomes. METHODS: The SOUL trial (Semaglutide Cardiovascular Outcomes Trial; NCT03914326) randomized 9650 participants with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease to oral semaglutide or placebo. As prespecified, participants were analyzed according to baseline use of SGLT2i (yes, n=2596; no, n=7054), and subsequently for any use of SGLT2i during the trial (yes, n=4718; no, n=4932). The primary outcome was time to first major adverse cardiovascular event, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Safety was evaluated by comparing the incidence of serious adverse events. RESULTS: Over a mean follow-up of 47.5±10.9 months, the risk of the primary outcome in the overall trial population was 14% lower for oral semaglutide versus placebo (hazard ratio, 0.86; 95% CI, 0.77-0.96). In those taking SGLT2i at baseline, there were 143 of 1296 (semaglutide) versus 158 of 1300 (placebo) primary outcome events (hazard ratio, 0.89; 95% CI, 0.71-1.11); and 436 of 3529 versus 510 of 3525, respectively, in participants not taking SGLT2i at baseline (hazard ratio, 0.84; 95% CI, 0.74-0.95; P-interaction, 0.66). An analysis of major adverse cardiovascular events by any in-trial SGLT2i use versus no use also showed no evidence of heterogeneity in the effects of oral semaglutide. The adverse event profiles of oral semaglutide with or without concomitant SGLT2i were similar. CONCLUSIONS: Oral semaglutide reduced major adverse cardiovascular event outcomes independently of concomitant SGLT2i treatment, and this combination appeared to be safe. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03914326.

KM 提取结果

1 个 Figure · 5 个 KM 面板

进入结果中心
KM Figure5 个面板

Figure 1

Figure 1. Cumulative incidence plots of outcomes for oral semaglutide vs placebo in subgroups with or without SGLT2i use at baseline. A , Time to first occurrence of MACE. B , Time to cardiovascular death. C , Time to first nonfatal myocardial infarction event. D , Time to first nonfatal stroke event. E , Time to all-cause death. The cumulative incidence rate is calculated using the Aalen-Johansen method with noncardiovascular death ( A and B )/all-cause death ( C and D ) as a competing risk. CV indicates cardiovascular; HR, hazard ratio; MACE, major adverse cardiovascular event; MI, myocardial infarction; and SGLT2i, sodium-glucose cotransporter-2 inhibitor

A

Time to first occurrence of MACE

Figure 1 · Panel A

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

Time to cardiovascular death

Figure 1 · Panel B

quality_warning 待 EXE 对齐 预期 4 条 已提取 2 条

Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

Time to first nonfatal myocardial infarction event

Figure 1 · Panel C

quality_warning 待 EXE 对齐 预期 4 条 已提取 1 条

Panel C 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 4 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 1:off origin start
查看结果
D

Time to first nonfatal stroke event

Figure 1 · Panel D

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel D 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 4 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 1:flat topline artifact
查看结果
E

Time to all-cause death

Figure 1 · Panel E

quality_warning 待 EXE 对齐 预期 4 条 已提取 1 条

Panel E 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 4 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 2:extreme jump
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2Figure 2. Forest plot: primary outcomes, components and all-cause death according to SGLT2i use at baseline. Data from the in-trial period. Time from randomization to relevant end point was analyzed using a Cox proportional hazards model with treatment as categorical fixed factor. Participants without events of interest were censored at the end of their in-trial period. For the subgroup analyses, estimated HRs and corresponding CIs are calculated in a Cox proportional hazards model with interaction between treatment group and subgroup as fixed factor. P -value, P value for the test of no interaction effect. CV indicates cardiovascular; HR, hazard ratio; MACE, major adverse cardiovascular event; MI, myocardial infarction; and SGLT2i, sodium-glucose cotransporter-2 inhibitor.
非 KM Figure
Figure 3Figure 3. Forest plot: cardiovascular outcomes according to SGLT2i use at baseline, by cardiovascular and kidney subgroups. A , ASCVD. B , CKD. C , ASCVD and CKD. Each plot shows data from the in-trial period. Time from randomization to relevant end point was analyzed using a Cox proportional hazards model with treatment as a fixed factor. Participants without events of interest were censored at the end of their in-trial period. For the subgroup analyses, estimated HRs and corresponding CIs are calculated in a Cox proportional hazards model with interaction between treatment group and subgroup as fixed factor. P -value, P value for the test of no interaction effect. ASCVD indicates atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CV, cardiovascular; HR, hazard ratio; MACE, major adverse cardiovascular event; MI, myocardial infarction; and SGLT2i, sodium-glucose cotransporter-2 inhibitor.
非 KM Figure